Alnylam Pharmaceuticals (NASDAQ:ALNY) PT Raised to $240.00

Alnylam Pharmaceuticals (NASDAQ:ALNYGet Rating) had its target price lifted by analysts at Needham & Company LLC from $205.00 to $240.00 in a note issued to investors on Thursday, Marketbeat reports. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. Needham & Company LLC’s price target suggests a potential upside of 9.80% from the company’s current price.

Several other equities research analysts have also issued reports on the stock. Citigroup increased their target price on shares of Alnylam Pharmaceuticals from $206.00 to $280.00 in a report on Thursday. SVB Leerink increased their target price on shares of Alnylam Pharmaceuticals from $96.00 to $98.00 and gave the stock a “market perform” rating in a report on Wednesday, June 15th. HC Wainwright increased their price objective on shares of Alnylam Pharmaceuticals from $400.00 to $430.00 in a report on Monday, May 2nd. Guggenheim lowered shares of Alnylam Pharmaceuticals from a “buy” rating to a “neutral” rating in a report on Monday, June 27th. Finally, William Blair assumed coverage on shares of Alnylam Pharmaceuticals in a report on Tuesday, June 7th. They set an “outperform” rating for the company. Six equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Alnylam Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $225.75.

Alnylam Pharmaceuticals Price Performance

NASDAQ ALNY opened at $218.58 on Thursday. Alnylam Pharmaceuticals has a 52 week low of $117.58 and a 52 week high of $226.00. The firm has a market capitalization of $26.24 billion, a P/E ratio of -26.75 and a beta of 0.74. The company has a quick ratio of 3.62, a current ratio of 3.76 and a debt-to-equity ratio of 3.85. The company has a 50-day moving average price of $145.22 and a 200-day moving average price of $147.90.

Alnylam Pharmaceuticals (NASDAQ:ALNYGet Rating) last released its earnings results on Thursday, July 28th. The biopharmaceutical company reported ($2.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.62) by ($0.67). The firm had revenue of $224.80 million during the quarter, compared to analysts’ expectations of $256.06 million. Alnylam Pharmaceuticals had a negative return on equity of 204.18% and a negative net margin of 110.91%. The company’s revenue was up 1.9% compared to the same quarter last year. During the same period in the prior year, the company posted ($1.61) earnings per share. Equities research analysts anticipate that Alnylam Pharmaceuticals will post -7.86 earnings per share for the current year.

Insider Buying and Selling

In related news, EVP Tolga Tanguler sold 1,754 shares of the firm’s stock in a transaction on Wednesday, August 3rd. The stock was sold at an average price of $210.00, for a total value of $368,340.00. Following the completion of the sale, the executive vice president now directly owns 3,629 shares in the company, valued at $762,090. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Insiders sold a total of 5,349 shares of company stock worth $1,033,073 over the last three months. 1.40% of the stock is owned by insiders.

Institutional Trading of Alnylam Pharmaceuticals

Institutional investors have recently bought and sold shares of the stock. Gateway Investment Advisers LLC lifted its position in Alnylam Pharmaceuticals by 474.4% in the first quarter. Gateway Investment Advisers LLC now owns 26,239 shares of the biopharmaceutical company’s stock worth $4,285,000 after buying an additional 21,671 shares during the last quarter. Shell Asset Management Co. lifted its position in Alnylam Pharmaceuticals by 54.7% in the fourth quarter. Shell Asset Management Co. now owns 5,808 shares of the biopharmaceutical company’s stock worth $985,000 after buying an additional 2,053 shares during the last quarter. Spire Wealth Management lifted its position in Alnylam Pharmaceuticals by 188.5% in the first quarter. Spire Wealth Management now owns 1,350 shares of the biopharmaceutical company’s stock worth $221,000 after buying an additional 882 shares during the last quarter. DNB Asset Management AS lifted its position in Alnylam Pharmaceuticals by 9.6% in the first quarter. DNB Asset Management AS now owns 21,355 shares of the biopharmaceutical company’s stock worth $3,487,000 after buying an additional 1,868 shares during the last quarter. Finally, Clearstead Advisors LLC increased its stake in Alnylam Pharmaceuticals by 3.7% in the fourth quarter. Clearstead Advisors LLC now owns 3,110 shares of the biopharmaceutical company’s stock worth $527,000 after purchasing an additional 110 shares during the period. 92.39% of the stock is currently owned by institutional investors.

About Alnylam Pharmaceuticals

(Get Rating)

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases.

Recommended Stories

Analyst Recommendations for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.